Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

APLT - Applied Therapeutics Inc.

IEX Last Trade
0.8518
0.002   0.223%

Share volume: 111,793
Last Updated: Thu 26 Dec 2024 08:30:14 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$0.85
0.00
0.22%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 25%
Dept financing 4%
Liquidity 50%
Performance 23%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.74%
1 Month
-91.66%
3 Months
-89.87%
6 Months
-80.91%
1 Year
-71.80%
2 Year
6.74%
Key data
Stock price
$0.85
P/E Ratio 
0.00
DAY RANGE
$0.77 - $0.86
EPS 
$0.00
52 WEEK RANGE
$0.88 - $10.62
52 WEEK CHANGE
-$72.53
MARKET CAP 
728.125 M
YIELD 
N/A
SHARES OUTSTANDING 
114.846 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.67
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$6,897,910
AVERAGE 30 VOLUME 
$12,322,018
Company detail
CEO: Shoshana Shendelman
Region: US
Website: www.appliedtherapeutics.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosmia in healthy volunteers and adults. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for treatment of diabetic peripheral neuropathy.

Recent news